Sentiment-Signal
18,8
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 27.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 20.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 16.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 25.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 20.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 05.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
Stammdaten
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Unternehmen & Branche
| Name | Niagen Bioscience, Inc. |
|---|---|
| Ticker | NAGE |
| CIK | 0001386570 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2833 · Medicinal Chemicals & Botanical Products |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 388,0 Mio. USD |
| Beta | 2,24 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 129,423,000 | 17,382,000 | 0.20 | 106,406,000 | 76,533,000 |
| 2025-09-30 | 10-Q | 33,986,000 | 4,578,000 | 0.05 | 98,139,000 | 70,676,000 |
| 2025-06-30 | 10-Q | 31,117,000 | 3,609,000 | 0.04 | 91,525,000 | 64,195,000 |
| 2025-03-31 | 10-Q | 30,481,000 | 5,063,000 | 0.06 | 81,337,000 | 55,345,000 |
| 2024-12-31 | 10-K | 99,597,000 | 8,550,000 | 0.11 | 68,278,000 | 46,094,000 |
| 2024-09-30 | 10-Q | 25,580,000 | 1,878,000 | 0.02 | 56,522,000 | 34,369,000 |
| 2024-06-30 | 10-Q | 22,739,000 | -15,000 | 0.00 | 54,035,000 | 30,718,000 |
| 2024-03-31 | 10-Q | 22,153,000 | -492,000 | -0.01 | 54,079,000 | 28,951,000 |
| 2023-12-31 | 10-K | 83,570,000 | -4,938,000 | -0.07 | 54,964,000 | 28,456,000 |
| 2023-09-30 | 10-Q | 19,495,000 | -959,000 | -0.01 | 53,483,000 | 27,308,000 |
| 2023-06-30 | 10-Q | 20,323,000 | -2,191,000 | -0.03 | 53,171,000 | 27,150,000 |
| 2023-03-31 | 10-Q | 22,556,000 | -1,902,000 | -0.03 | 53,768,000 | 28,017,000 |
| 2022-12-31 | 10-K | 72,050,000 | -16,540,000 | -0.24 | 54,057,000 | 28,672,000 |
| 2022-09-30 | 10-Q | 17,063,000 | -985,000 | -0.01 | 45,665,000 | 21,023,000 |
| 2022-06-30 | 10-Q | 16,732,000 | -6,397,000 | -0.09 | 46,613,000 | 20,778,000 |
| 2022-03-31 | 10-Q | 17,259,000 | -7,740,000 | -0.11 | 52,930,000 | 25,877,000 |
| 2021-12-31 | 10-K | 67,449,000 | -27,128,000 | -0.40 | 57,840,000 | 31,727,000 |
| 2021-09-30 | 10-Q | 17,308,000 | -8,856,000 | -0.13 | 60,452,000 | 35,449,000 |
| 2021-06-30 | 10-Q | 17,699,000 | -5,566,000 | -0.08 | 65,842,000 | 42,142,000 |
| 2021-03-31 | 10-Q | 14,683,000 | -7,381,000 | -0.12 | 68,993,000 | 43,832,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-14 | Pamir Ozan | Officer, Chief Financial Officer | Open Market Purchase | 2,220 | 6.85 | 15,210.03 | +66,7% | |
| 2025-11-14 | Pamir Ozan | Officer, Chief Financial Officer | Open Market Purchase | 4,465 | 6.81 | 30,406.39 | +133,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.